Tandem Diabetes Care closes IPO; Honda starts tests on rehab exoskeleton;

@FierceMedDev: ResMed wins German court injunction against two respiratory device patent rivals. More | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B settlement addresses thousands of lawsuits over faulty metal hip implants but many will remain in play. Story | Follow @MarkHFierce

> Tandem Diabetes Care ($TNDM) has officially closed its initial public offering, which involved more than 9.2 million shares at $15 a piece. Item

> Honda is pursuing its first large-scale clinical trial of a battery and motor-powered exoskeleton designed to help patients improve their mobility in a physical rehabilitation setting. Story

> Cutting-edge camera maker Lytro raised an additional $40 million in funding to fuel a redesigned device featuring technology the company touts as having appeal to medical-device makers. Story

> The FDA hit devicemaker Avacen with a warning letter for a number of quality system violations involving its thermal exchange system product. Warning letter

> A number of manufacturers have linked up to develop a more streamlined and safer manufacturing process for implantable medical devices. Item

Biotech News

@FierceBiotech: Clovis bets up to $420M on targeted cancer drug. News | Follow @FierceBiotech

@JohnCFierce: Great talk with Missouri Bio and KansasBio today. About half read Fierce on their cell phones. New day and new media. | Follow @JohnCFierce

@DamianFierce: Meet Rebecca Friend, publisher of the FierceBiotech family of publications. More | Follow @DamianFierce

@EmilyMFierce: News about Art Levinson's Calico breaks on... Google+? Story | Follow @EmilyMFierce

>  Argos rakes in $17.5M more to wrap up PhIII for cancer drug. More

>  Moderna nails $110M to get mRNA tech into the clinic. Article

>  BioMarin skates through FDA panel for rare disease drug. News

>  Google's Calico poaches Roche guru Barron to steer R&D. Article

Pharma News

@FiercePharma: Best-read new news Tuesday: Can Teva find a partner to save it from itself? Story | Follow @FiercePharma

@EricPFierce: GSK continues to lead with continuous processing. Will use technology at $136.5 million plant in India. More | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> Ex-Teva chief Jeremy Levin to MBA grads: Anyone have a job for me? Story

> Daiichi clot-fighter aces study, but can it compete with Pradaxa, Xarelto and Eliquis? Article

Drug Delivery News

@MichaelGFierce: Delivery guru Robert Langer discusses nanomeds, up-and-coming ventures, new frontiers. Editor's corner | Follow @MichaelGFierce

> Unilife signs $80M deal to supply Hikma with prefilled syringes. Story

> FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. Article

> Svelte begins pivotal trial for drug-eluting stent. Report

> Study: Genes delivered directly to heart stymie heart failure. More

> Dual-wave approach clears path for cancer drug delivery. Story

> Oramed wins European patent for insulin pill tech. Item

Diagnostics News

> GenapSys nails down $37M to advance next-generation gene sequencing tech. Article

> Trovagene pledges results, in part, from cancer urine test launch. Report

> Houston Methodist-led team shows potential of early breast cancer blood Dx. More

> Atossa makes headway in getting breast cancer test back to market. Article

> FDA OKs 4 Illumina next-generation sequencing devices. Report

> Johns Hopkins approach shows promise in early dementia diagnosis. Item